Pluri Inc. Files 8-K: Material Agreement, Equity Sales, Officer Changes

TL;DR

Pluri Inc. signed a big deal, sold some stock, and shuffled execs. Big changes ahead?

AI Summary

On December 8, 2025, Pluri Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and changes in its board and officer composition, including compensatory arrangements. This filing also covers other events and financial statements/exhibits.

Why It Matters

This 8-K filing indicates significant corporate actions at Pluri Inc., including a new material agreement and equity transactions, which could impact its financial standing and strategic direction.

Risk Assessment

Risk Level: medium — The filing details a material definitive agreement and unregistered equity sales, which can introduce financial and operational risks.

Key Players & Entities

• Pluri Inc. (company) — Filer of the 8-K report
• 0001158780 (company) — Central Index Key for Pluri Inc.
• 20251208 (date) — Date of report
• 20251209 (date) — Filing date

FAQ

Key Financial Figures

• $0.00001 — h registered Common Shares, par value $0.00001 per share PLUR The Nasdaq Capital M
• $4.00 — each Common Share and Common Warrant is $4.00. The Common Warrants will be exercisabl
• $4.25 — ble immediately at an exercise price of $4.25 per share and will be exercisable until
• $2.5 million — fering are expected to be approximately $2.5 million. The Company intends to use the proceed

Filing Documents

• ea0269001-8k_pluri.htm (8-K) — 34KB
• ea026900101ex4-1_pluri.htm (EX-4.1) — 83KB
• ea026900101ex10-1_pluri.htm (EX-10.1) — 213KB
• 0001213900-25-119651.txt ( ) — 567KB
• plur-20251208.xsd (EX-101.SCH) — 3KB
• plur-20251208_lab.xml (EX-101.LAB) — 33KB
• plur-20251208_pre.xml (EX-101.PRE) — 22KB
• ea0269001-8k_pluri_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On December 8, 2025, Pluri Inc. (the "Company") entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with Chutzpah Holdings LP (the "Purchaser"), a limited partnership beneficially owned by Mr. Alexandre Weinstein, a non-U.S. investor and an existing shareholder and director of the Company ("Mr. Weinstein"), relating to a private placement offering (the "Offering") of: (i) 625,000 common shares, par value $0.00001 per share (the "Common Shares") of the Company, and (ii) warrants (the "Common Warrants") to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and Common Warrant is $4.00. The Common Warrants will be exercisable immediately at an exercise price of $4.25 per share and will be exercisable until June 30, 2026. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The Securities Purchase Agreement contains customary representations, warranties and indemnification obligations of the parties. The gross proceeds to the Company from the Offering are expected to be approximately $2.5 million. The Company intends to use the proceeds from the Offering for working capital and general corporate purposes. The Offering is expected to close on or about December 15, 2025, The securities issued with respect to the Offering are exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), pursuant to Section 4(a)(2) of the Securities Act and/or Rule 903 of Regulation S promulgated thereunder. The securities have not been registered under the Securities Act and may not be sold in the United States absent registration or an exemption from registration. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any

02 Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities. The response to this item is included in Item 1.01, Entry into a Material Definitive Agreement, and is incorporated herein in its entirety.

02 Departure of Directors or Certain

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 4, 2025, the Company's board of directors (the "Board") granted an aggregate of 10,248 restricted stock units ("RSUs") to the Chief Executive Officer and Chief Financial Officer and an aggregate of 2,885 RSUs to Board members in lieu of cash compensation under the Company's 2019 Equity Compensation Plan, with all RSUs vesting in equal monthly installments over three months. These grants were made to support the Company's cost-management initiatives and to align leadership incentives with long-term performance objectives.

01 Other Events

Item 8.01 Other Events. Effective December 4, 2025, Mr. Weinstein was appointed by the Board as Chairman of the Board, and Mr. Zami Aberman was appointed by the Board as Vice Chairman of the Board. In connection therewith, Mr. Aberman's consultancy agreement with the Company will be terminated effective January 4, 2026. 1

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 4.1 Form of Warrant 10.1 Securities Purchase Agreement 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Safe Harbor Statement This Current Report on Form 8-K contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, the Company is using forward-looking statements when it discusses the expected closing of the Offering, the receipt of the proceeds from the Offering and the intended use of the proceeds from the Offering. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about the Company: the conditions to the closing of the Offering may not be met; changes in technology and market requirements; the Company may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; the Company's products may not be approved by regulatory agencies; the Company's technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; the Company may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with the Company's processes; the Company's products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; the Company's patents may not be sufficient; the Company's produc

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PLURI INC. Date: December 9, 2025 By: /s/ Liat Zalts Name: Liat Zalts Title: Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR